Rohit Jadhav, PHD
Dr. Rohit Jadhav joined Juvena Therapeutics in August 2022, bringing more than 12 years of cross disciplinary experience encompassing the fields of oncology, immune aging and auto-immune diseases. He has extensive experience in algorithm development for diagnostic and prognostic biomarker discovery dealing with diverse datasets investigating the Transcriptome, Epigenome and DNA mutations in clinical cohorts.
Dr. Jadhav earned his B.Tech. in Bioinformatics from India, a M.S. in Bioinformatics from Indiana University, Indianapolis, a PhD in Molecular Medicine from UT Health, San Antonio as a CPRIT pre-doctoral fellow, followed by a postdoctoral fellowship in Immunology at Stanford School of Medicine and Mayo Clinic.
Masters & PhD (2009-2016)
Dr. Jadhav worked on identifying epigenetic biomarkers investigating alterations in DNA methylation across different cancer types including breast, ovarian, endometrial, oral and prostate. He was awarded a Cancer Prevention and Research Institute of Texas (CPRIT) Predoctoral Fellowship, which enabled him to be involved in collaborative projects focusing on non-invasive approaches for biomarker discovery. One such project involved use of single-cell RNA sequencing to study circulating tumor cells and another involved studying DNA methylation in cell free DNA, both from peripheral blood. As a lead bioinformatician for these studies, he implemented classification-based prediction methods to enable identification of a panel of biomarkers to be used in determining treatment approaches for prostate cancer patients belonging to different subtypes. These studies have led to 3 approved patents from his mentor Dr. Tim Huang. During this time, Dr. Jadhav was also a lead author on the study that identified DNA methylation biomarkers capable of identifying predisposition to breast cancer after prenatal exposure to the compound bisphenol A and preventive effects of genistein.
Postdoctoral Fellowship (2017-2022)
Dr. Jadhav’s work at Stanford University and Mayo Clinic with Dr. Jorg Goronzy who is a leading expert in immune aging and auto-immunity, focused on epigenetics in the context of chromatin accessibility and specifically alterations in the immune cell types like CD4 and CD8 T cells during aging and autoimmune diseases like rheumatoid arthritis. He was also a lead author studying epigenetic alterations in exhausted T-cells post checkpoint blockade therapies in collaboration with Dr. Rafi Ahmed from Emory University. During this time Dr. Jadhav built pipelines deployed in on-prem clusters and in the cloud for analyzing and visualizing data from RNA-seq, ATAC-seq, TCR-seq, single cell multiome (RNA+ATAC) , single cell Cite-seq (RNA+Protein) among others.
Dr. Jadhav has published over 30 peer-reviewed papers with over a thousand citations.
Learn more about Rohit Jadhav